217 related articles for article (PubMed ID: 29739251)
1. Heparan Sulfate Binding Coxsackievirus B3 Strain PD: A Novel Avirulent Oncolytic Agent Against Human Colorectal Carcinoma.
Hazini A; Pryshliak M; Brückner V; Klingel K; Sauter M; Pinkert S; Kurreck J; Fechner H
Hum Gene Ther; 2018 Nov; 29(11):1301-1314. PubMed ID: 29739251
[TBL] [Abstract][Full Text] [Related]
2. Heparan sulfates and coxsackievirus-adenovirus receptor: each one mediates coxsackievirus B3 PD infection.
Zautner AE; Körner U; Henke A; Badorff C; Schmidtke M
J Virol; 2003 Sep; 77(18):10071-7. PubMed ID: 12941917
[TBL] [Abstract][Full Text] [Related]
3. Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma.
Miyamoto S; Inoue H; Nakamura T; Yamada M; Sakamoto C; Urata Y; Okazaki T; Marumoto T; Takahashi A; Takayama K; Nakanishi Y; Shimizu H; Tani K
Cancer Res; 2012 May; 72(10):2609-21. PubMed ID: 22461509
[TBL] [Abstract][Full Text] [Related]
4. N- and 6-O-sulfated heparan sulfates mediate internalization of coxsackievirus B3 variant PD into CHO-K1 cells.
Zautner AE; Jahn B; Hammerschmidt E; Wutzler P; Schmidtke M
J Virol; 2006 Jul; 80(13):6629-36. PubMed ID: 16775350
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic activity of a coxsackievirus B3 strain in human endometrial cancer cell lines.
Lin Y; Wang W; Wan J; Yang Y; Fu W; Pan D; Cai L; Cheng T; Huang X; Wang Y
Virol J; 2018 Apr; 15(1):65. PubMed ID: 29631630
[TBL] [Abstract][Full Text] [Related]
6. Application Route and Immune Status of the Host Determine Safety and Oncolytic Activity of Oncolytic Coxsackievirus B3 Variant PD-H.
Hazini A; Dieringer B; Klingel K; Pryshliak M; Geisler A; Kobelt D; Daberkow O; Kurreck J; Linthout SV; Fechner H
Viruses; 2021 Sep; 13(10):. PubMed ID: 34696348
[TBL] [Abstract][Full Text] [Related]
7. Coxsackievirus B3-Its Potential as an Oncolytic Virus.
Geisler A; Hazini A; Heimann L; Kurreck J; Fechner H
Viruses; 2021 Apr; 13(5):. PubMed ID: 33919076
[TBL] [Abstract][Full Text] [Related]
8. Attachment of coxsackievirus B3 variants to various cell lines: mapping of phenotypic differences to capsid protein VP1.
Schmidtke M; Selinka HC; Heim A; Jahn B; Tonew M; Kandolf R; Stelzner A; Zell R
Virology; 2000 Sep; 275(1):77-88. PubMed ID: 11017789
[TBL] [Abstract][Full Text] [Related]
9. A decay-accelerating factor-binding strain of coxsackievirus B3 requires the coxsackievirus-adenovirus receptor protein to mediate lytic infection of rhabdomyosarcoma cells.
Shafren DR; Williams DT; Barry RD
J Virol; 1997 Dec; 71(12):9844-8. PubMed ID: 9371658
[TBL] [Abstract][Full Text] [Related]
10. A Novel Combination Therapy for Human Oxaliplatin-resistant Colorectal Cancer Using Oxaliplatin and Coxsackievirus A11.
Wang B; Ogata H; Takishima Y; Miyamoto S; Inoue H; Kuroda M; Yamada K; Hijikata Y; Murahashi M; Shimizu H; Okazaki T; Nakanishi Y; Tani K
Anticancer Res; 2018 Nov; 38(11):6121-6126. PubMed ID: 30396927
[TBL] [Abstract][Full Text] [Related]
11. Development of New Oncolytic Virotherapy Targeting Breast Cancer Using Coxsackievirus B3.
Sagara M; Miyamoto S; Itoh S; Soda Y; Tani K
Anticancer Res; 2021 Jan; 41(1):81-89. PubMed ID: 33419801
[TBL] [Abstract][Full Text] [Related]
12. Comparative analysis of two coxsackievirus B3 strains: putative influence of virus-receptor interactions on pathogenesis.
Selinka HC; Wolde A; Pasch A; Klingel K; Schnorr JJ; Küpper JH; Lindberg AM; Kandolf R
J Med Virol; 2002 Jun; 67(2):224-33. PubMed ID: 11992583
[TBL] [Abstract][Full Text] [Related]
13. Expression and distribution of the receptors for coxsackievirus B3 during fetal development of the Balb/c mouse and of their brain cells in culture.
Xu R; Crowell RL
Virus Res; 1996 Dec; 46(1-2):157-70. PubMed ID: 9029788
[TBL] [Abstract][Full Text] [Related]
14. Single-Point Mutations within the Coxsackie B Virus Receptor-Binding Site Promote Resistance against Soluble Virus Receptor Traps.
Pinkert S; Kopp A; Brückner V; Fechner H; Beling A
J Virol; 2020 Sep; 94(19):. PubMed ID: 32669334
[TBL] [Abstract][Full Text] [Related]
15. Soluble recombinant coxsackievirus and adenovirus receptor abrogates coxsackievirus b3-mediated pancreatitis and myocarditis in mice.
Yanagawa B; Spiller OB; Proctor DG; Choy J; Luo H; Zhang HM; Suarez A; Yang D; McManus BM
J Infect Dis; 2004 Apr; 189(8):1431-9. PubMed ID: 15073680
[TBL] [Abstract][Full Text] [Related]
16. miR-375- and miR-1-Regulated Coxsackievirus B3 Has No Pancreas and Heart Toxicity But Strong Antitumor Efficiency in Colorectal Carcinomas.
Hazini A; Dieringer B; Pryshliak M; Knoch KP; Heimann L; Tolksdorf B; Pappritz K; El-Shafeey M; Solimena M; Beling A; Kurreck J; Klingel K; Fechner H
Hum Gene Ther; 2021 Feb; 32(3-4):216-230. PubMed ID: 33481658
[TBL] [Abstract][Full Text] [Related]
17. NOD2 (Nucleotide-Binding Oligomerization Domain 2) Is a Major Pathogenic Mediator of Coxsackievirus B3-Induced Myocarditis.
Tschöpe C; Müller I; Xia Y; Savvatis K; Pappritz K; Pinkert S; Lassner D; Heimesaat MM; Spillmann F; Miteva K; Bereswill S; Schultheiss HP; Fechner H; Pieske B; Kühl U; Van Linthout S
Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28912259
[TBL] [Abstract][Full Text] [Related]
18. Combination of RNA interference and virus receptor trap exerts additive antiviral activity in coxsackievirus B3-induced myocarditis in mice.
Stein EA; Pinkert S; Becher PM; Geisler A; Zeichhardt H; Klopfleisch R; Poller W; Tschöpe C; Lassner D; Fechner H; Kurreck J
J Infect Dis; 2015 Feb; 211(4):613-22. PubMed ID: 25193982
[TBL] [Abstract][Full Text] [Related]
19. Treatment of coxsackievirus-B3-infected BALB/c mice with the soluble coxsackie adenovirus receptor CAR4/7 aggravates cardiac injury.
Dörner A; Grunert HP; Lindig V; Chandrasekharan K; Fechner H; Knowlton KU; Isik A; Pauschinger M; Zeichhardt H; Schultheiss HP
J Mol Med (Berl); 2006 Oct; 84(10):842-51. PubMed ID: 16924471
[TBL] [Abstract][Full Text] [Related]
20. Hepatic damage caused by coxsackievirus B3 is dependent on age-related tissue tropisms associated with the coxsackievirus-adenovirus receptor.
Liu JY; Wang SM; Chen IC; Yu CK; Liu CC
Pathog Dis; 2013 Jul; 68(2):52-60. PubMed ID: 23620416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
